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Prospective purification of perivascular
presumptive mesenchymal stem cells from
human adipose tissue: process optimization
and cell population metrics across a large
cohort of diverse demographics
C. C. West1,2†, W. R. Hardy3†, I. R. Murray1†, A. W. James3, M. Corselli3,4, S. Pang3, C. Black3,5, S. E. Lobo3,6,
K. Sukhija3,7, P. Liang3,8, V. Lagishetty3,9, D. C. Hay1, K. L. March10, K. Ting3,11, C. Soo3,12,13 and B. Péault1,3*
Abstract
Background: Adipose tissue is an attractive source of mesenchymal stem cells (MSC) as it is largely dispensable
and readily accessible through minimally invasive procedures such as liposuction. Until recently MSC could only be
isolated in a process involving ex-vivo culture and their in-vivo identity, location and frequency remained elusive. We
have documented that pericytes (CD45-, CD146+, and CD34-) and adventitial cells (CD45-, CD146-, CD34+) (collectively
termed perivascular stem cells or PSC) represent native ancestors of the MSC, and can be prospectively purified using
fluorescence activated cell sorting (FACS). In this study we describe an optimized protocol that aims to deliver pure,
viable and consistent yields of PSC from adipose tissue. We analysed the frequency of PSC within adipose tissue, and
the effect of patient and procedure based variables on this yield.
Methods: Within this twin centre study we analysed the adipose tissue of n = 131 donors using flow cytometry to
determine the frequency of PSC and correlate this with demographic and processing data such as age, sex, BMI and
cold storage time of the tissue.
Results: The mean number of stromal vascular fraction (SVF) cells from 100 ml of lipoaspirate was 34.4 million. Within
the SVF, mean cell viability was 83 %, with 31.6 % of cells being haematopoietic (CD45+). Adventitial cells and pericytes
represented 33.0 % and 8 % of SVF cells respectively. Therefore, a 200 ml lipoaspirate would theoretically yield 23.2
million viable prospectively purified PSC - sufficient for many reconstructive and regenerative applications. Minimal
changes were observed in respect to age, sex and BMI suggesting universal potential application.
(Continued on next page)
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Conclusions: Adipose tissue contains two anatomically and phenotypically discreet populations of MSC
precursors – adventitial cells and pericytes – together referred to as perivascular stem cells (PSC). More than 9
million PSC per 100 ml of lipoaspirate can be rapidly purified to homogeneity using flow cytometry in
clinically relevant numbers potentially circumventing the need for purification and expansion by culture prior
to clinical use. The number and viability of PSC are minimally affected by patient age, sex, BMI or the storage
time of the tissue, but the quality and consistency of yield can be significantly influenced by procedure
based variables.
Keywords: Mesenchymal stem cells, Adipose tissue, Adipose-derived stem cell, Cell sorting, Flow cytometry,
Pericyte, Tunica adventitia
Background
In a series of pioneering experiments in the 1960s,
Alexander Friedenstein et al. [1] identified a population
of cells from rodent bone marrow that adhered to culture
vessels, formed colonies, could differentiate into osteoblasts
in culture, and generated bone when implanted ectopically
in vivo [2, 3]. Friedenstein termed these cells colony form-
ing unit fibroblast (CFU-F), until Arnold Caplan [4], in the
early 1990s, coined the term mesenchymal stem cells
(MSC). Since their initial description, these cells have been
the focus of much attention for their ability to differentiate
into multiple mesodermal cell lineages, to modulate the
immune system, and to stimulate regeneration through
trophic support and the secretion of cytokines [5].
Despite the ultimate desire to translate MSC research
into novel therapies, our understanding of these cells had
been based principally on observations made in vitro on
cells of undocumented purity and homogeneity, in ignor-
ance of their anatomical location and physiological role in
natural and pathological processes. MSC have been
enlisted from bone marrow and multiple other tissues, ac-
cording to their ability to adhere and grow on plastic [6].
This suggested that these cells possess a common identity
and a widespread anatomical distribution but provided
little insight into location, cellular phenotype, frequency,
and specific properties of these cells. Some of these ques-
tions were answered when Crisan et al. [7] demonstrated
that microvascular pericytes in multiple human fetal and
adult tissues express MSC markers, and that when puri-
fied to homogeneity by fluorescence-activated cell sorting
(FACS) and cultured they are identical to conventional
MSCs in terms of morphology, phenotype, and function.
This led to the conclusion that pericytes, defined as
CD31−CD45−CD34−CD146+, represent an origin of the
MSC grown in culture, a finding that has been validated
by other groups [8, 9]. Subsequently, a second population
of anatomically and phenotypically distinct CD31–CD45–
CD34+CD146– cells with identical function to conven-
tional MSCs has been identified that reside in the adventi-
tial layer of larger blood vessels [10, 11]. Henceforth, we
will refer to these two populations collectively as
perivascular stem cells (PSC). Since their description,
PSC have been confirmed to behave in vitro and in
vivo like MSC, and to be equal in function, if not su-
perior in some instances, to other stem and progeni-
tor populations (reviewed in [12]).
Despite promising findings, there are challenges to ad-
dress prior to the successful translation and wider clinical
use of MSC. Because these cells are procured in low yield
from tissues such as bone marrow, they are typically ex-
panded and “purified” based on adherence to plastic under
Good Manufacturing Practice compliant conditions—a
costly, labor-intensive, and extended process requiring ex
vivo culture prior to transplantation. The potential risks
entailed by in vitro expansion include infection and im-
munogenicity due to the exposure of cultured cells to
animal-based supplements [13]. Extended periods of in
vitro expansion adversely impact the function of these
cells, resulting in reductions in their chondrogenic, adipo-
genic, and osteogenic potentials [14–16]. Higher passage
cells show modified and diminished expression of chemo-
kine receptors and adhesion molecules resulting in lower
response to chemokines and increased senescence [17].
Concerns have also been raised about the development of
genetic instability and the potential for malignant trans-
formation in cultured cells. In addition there are signifi-
cantly more stringent regulatory hurdles that must be
addressed with the use of cultured cells compared with
those that have been minimally manipulated [18].
In an attempt to eliminate many of these issues, some
groups have investigated the use of an adipose-derived stro-
mal vascular fraction (SVF) as a source of MSC/progenitor
cells that bypasses the need for in vitro culture and may be
delivered at the point of use, requiring only basic preparation
such as enzymatic digestion, washing, and centrifugation.
Whilst the SVF may eliminate the requirement of ex vivo
expansion, it is a very heterogeneous cell population contain-
ing endothelial cells, hematopoietic and inflammatory cells,
and fibroblasts as well as cellular debris. This cellular hetero-
geneity may limit the regenerative potential of the SVF when
compared with a more homogeneous MSC population,
as has been demonstrated in models of osteogenesis [19].
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It is therefore clear that there is a dichotomy in the
current approaches to delivering MSC for clinical use.
Methods relying on in vitro culture as a means of selection
provide a relatively enriched but still undefined cell popula-
tion and in addition incur the practical, financial, ethical,
and regulatory problems this method manifests. Those
methods which use the SVF do so at the expense of prod-
uct identity, purity, and function. We have therefore sought
to develop methods for the prospective purification of
homogeneous populations of MSC based on our under-
standing of the exact anatomic location and identity of their
native ancestors. Using multicolor FACS, we have purified
cells from a range of human adult and fetal tissues [7, 12].
This early work was able to deliver distinct populations of
cells that were subsequently expanded in vitro for further
characterization, analysis, and experimental work. As our
interest in these cells has developed and their potential for
immediate clinical use was explored, we established that
large numbers of the cells recovered immediately from
FACS were of poor quality, and were in the process of
dying. This had been previously overlooked in our in-vitro
populations because only the healthy cells would adhere
and expand. For PSC to be used immediately after FACS,
we would need to demonstrate that it is possible to recover
pure, viable, and consistent yields of cells. We therefore
sought to refine our protocols to maximize not only total
cell yield, but maximum viable cell yield, purity, and
consistency leading to the development of an optimized
protocol that we describe in this work. Using this optimized
protocol, we document the cellular composition of hu-
man adipose tissue using flow cytometry across a wide
demography of donors, and to establish whether PSC
can be prospectively purified in clinically relevant num-
bers, circumventing the need for ex vivo expansion.
Furthermore we examined the patient and procedure
based variables that may influence this yield. Results
were collected from 131 individual lipoaspirates proc-
essed in two distinct research centers by different
investigators.
Methods
This was a twin-center study based at the University of
California at Los Angeles (UCLA), USA and the University
of Edinburgh, UK. Adipose tissue was collected with prior
written consent from patients undergoing cosmetic lipect-
omy procedures. Permission for the collection of tissue
and subsequent research was granted in Edinburgh by
the South East Scotland Research Ethics Committee
(Reference: 10/S1103/45), and was unnecessary in
Los Angeles because fat was collected under an institu-
tional review board exemption, being considered
medical waste.
Tissue was processed and flow cytometry performed
using our previously published protocols [12] and the
modifications detailed in this manuscript (Additional
file 1). Briefly, lipoaspirate was washed in phosphate
buffered saline and centrifuged to separate the fat from the
oil and liquid phases. Fat was combined vol/vol with 125
CDU/ml type II collagenase (collagenase from Clostridium
histolyticum, C6885; Sigma Aldrich, St Louis, Mo, USA) in
Dulbecco’s modified Eagle’s medium+ 3.5 % bovine serum
albumin (BSA) (Cohn Fraction V A7906; Sigma) and
digested for 45 minutes at 37 °C in a shaking water bath
(200 rpm). Samples were centrifuged to isolate the SVF
which was subsequently filtered through a 100 μm filter
and then a 70 μm filter before red cells were lysed. Finally,
the SVF was filtered through a 40 μm filter prior to manu-
ally counting live cells using trypan blue staining and a
hemocytometer. The SVF was then stained with the follow-
ing antibodies: CD31, CD34, and CD45 (all from BD Bio-
sciences, San Jose, CA, USA) and CD146 (AbD Serotec,
Raleigh, NC, USA). Flow cytometry was performed using a
BD FacsAria II or III sorter fitted with a 100 μm nozzle fol-
lowing adequate compensation controls using either single
stained cells or compensation beads. An initial forward
scatter (FSC) vs side scatter (SSC) gate was used to identify
cells, followed by gates to select for single cells. Cells not
stained by 4′,6-diamidino-2-phenylindole (DAPI) were
gated as viable, and hematopoietic and endothelial cells
were eliminated based on CD45 and CD31 expression
respectively. PSC were subsequently purified from the
CD31–/CD45– cell fraction according to their differential
expression of CD34 and CD146 (pericytes: CD146+,
CD34–, CD31–, CD45–; adventitial cells: CD146–, CD34+,
CD31–, CD45–) [7, 10].
Flow cytometry data were analyzed using FlowJo (v.
10.0, FlowJo, Ashland, OR, USA) or Diva (v. 6.0, BD
Biosciences, San Jose, CA, USA) software, and reviewed
by CCW, IRM, WRH, and BP to ensure that accurate
and standardized gating strategies were employed
across sites and between users. Statistical analysis was
performed using JMP10 software (SAS Institute Inc.,
Cary, NC, USA). Normally distributed nominal data
were analyzed using a paired t test, while bivariate fit
using regression analysis was used for continuous data.
Multivariate analysis was performed using multiple
linear least-squares regression. Data were considered
significant when p <0.05.
Results
Demographic and PSC parameter analysis
Demographic information as well as cell yield, viability,
and subpopulation sort statistics are summarized in
Table 1 for 131 unique donor samples.
Analysis of SVF
The SVF was isolated from total fat by collagenase diges-
tion. The mean yield of nucleated cells was 34.4 × 106
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per 100 ml of lipoaspirate (median: 30.0 × 106; standard
deviation (SD): ± 21.0 × 106; range: 4.7 × 106–120 × 106;
n = 131). Upon FACS analysis, an initial FSC vs SSC gate
was set to delimit PSC that occupy a characteristic
region of the cytogram in terms of size and internal
complexity amongst the diverse mixture of cells that
comprise the SVF. Significantly, this demonstrated that
the majority of the SVF in many samples is comprised of
dead and dying cells and cellular debris. Gating to select
single cells is necessary to prevent the collection of non-
PSC due to incomplete collagenase digestion and/or cell
aggregation post isolation and during the processing and
staining of the cells prior to sorting. Since collagenase
dissociated cells approximate a sphere, the height-to-width
ratio should maintain a constant value—or said differ-
ently, the height and width of the cells should scale pro-
portionally to the area. Single cell selection by FACS is
possible using the gating parameters shown in Fig. 1. Vi-
able cells possess an intact plasma membrane and ex-
clude DAPI, allowing cell viability to be assessed (mean
cell viability: 83 %; median: 84 %; SD: ±12 %; range:
36–99 %; n = 131). CD45+ haematopoietic cells and
CD31+ endothelial cells averaged 34 % (median: 33 %;
SD: ±16 %; range: 1–73 %; n = 113) and 4 % (median:
3 %; SD: ±4 %; range: 0.1–16 %; n = 17), respectively,
of total live cells in the SVF. The mean proportion of
PSCs was 41 % (median 42 %; SD: ±16 %; range: 6–78 %;
n = 124) with a mean proportion of pericytes of 8 %
(median 5 %; SD: 8 %; range: 0–55 %; n = 131), and
adventitial cells of 33 % (median 34 %; SD: ±16 %;
Table 1 Demographic data of the 131 donors
Demographic data (n = 131)
Sex Female = 112
Male = 19
Age (years) Mean = 41 (range 22–64)
BMI (kg/m2) Mean = 26.5 (range 19–43)
SVF (cells × 106) Mean = 34.4 (range 4.7–120)
Viability (%) Mean = 83 % (range 36–99)
Pericytes (%) Mean = 8 % (range 0–55)
Adventitial cells (%) Mean = 33.0 % (range 3–72)
PSC total (%) Mean = 41 % (range 6–78)
PSC yield (cells × 106) Mean = 11.6 (range 1.1–47.2)
BMI body mass index, PSC perivascular stem cell, SVF stromal vascular fraction
S
S
C
-H
DAPI
CD146CD31
FSC-H
F
S
C
-H
F
S
C
-H
F
S
C
-H
CD45
C
D
34
F
S
C
-H
FSC-A
1. 2. 3.
4. 5.
ADV
PERI
Fig. 1 Gating strategies for the isolation of PSC from the SVF. Gate 1 = cells, Gate 2 = single cells, Gate 3 = live cells, Gate 4 = CD45− (nonhaematopoietic
cells), Gate 5 = CD31– (nonendothelial cells), Gate ADV = adventitial cells (CD31−, CD45−, CD34+, CD146−), and Gate PERI = pericytes (CD31−,
CD45−, CD34+, CD146−). DAPI 4',6-diamidino-2-phenylindole, FSC forward scatter, SSC side scatter
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range: 3–72 %; n = 131). This represents a mean yield
of 11.6 × 106 PSCs (median 10.0 × 106; SD: 8.6 × 106;
range: 1.1 × 106–47.2 × 106; n = 124) per 100 ml of
lipoaspirate.
Effects of demographics on cell yield
The mean age of donors was 41 years (range: 22–64, n =
124 in Table 1). There were no differences observed in ei-
ther the total number of viable SVF cells or the proportion
of PSC as a percentage of live cells with age, with linear
correlation coefficients (R) of 0.07 and 0.09, respectively
(Fig. 2a, b). No statistical difference was observed in the
yield of SVF cells (p = 0.34) or viable PSC (p = 0.79)
between genders (Fig. 2c, 2d, respectively). Although the
proportion of PSC (as a percentage of live cells) was
significantly higher in male vs. female donors, with mean
PSC proportions of 47 % vs 40 %, respectively (p = 0.05,
one-tailed t test), the average SVF yield (male: 30 × 106
cells vs female: 35 × 106 cells) and cell viabilities (male:
82 % vs female: 83 %) were correspondingly lower,
although not significantly, in males, resulting in a zero
sum scenario (data not shown). Body mass index (BMI)
had no significant effect on either the total yield of SVF
cells or the proportion of PSC as a percentage of live cells
(R = 0.05 and 0.01, respectively; Fig. 2e, f ). Multivariate
analysis was performed using multiple linear least-squares
regression for all demographic data and cold storage
times, resulting in F ratio = 2.99, p = 0.035. The only factor
Fig. 2 a, b. Linear fit of SVF yield and PSC yield (× 106) per 100 ml of lipoaspirate with respect to donor age (n = 124, R = 0.07 and 0.09
respectively). c, d. One-way analysis of variance of SVF and PSC yields (× 106) vs donor gender (n = 131; male = 19, female = 112): green diamonds
reflect the mean yield (center line) and 95 % confidence interval (vertical span) for each gender, and the grand mean in gray. Linear fit of
SVF yield e and proportion of PSCs comprising the SVF f with respect to donor BMI (n = 97, R = 0.05 and 0.01 respectively). BMI body mass
index, F female, lipo lipoaspirate, M male, PSC perivascular stem cell, SVF stromal vascular fraction (Color figure online)
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within these parameters that demonstrated any significant
correlation to cell yield was the cold storage time (t ratio =
2.99, p = 0.004), which is discussed further below.
Effect of cold storage time on cell yield
After surgical removal, adipose tissue was stored at 4 °C
until analyzed. The majority of samples were processed
within 24 hours following surgery; however, some
samples were stored for up to 7 days. When split into
discreet time points and analyzed using the Tukey–Kramer
(honest significant difference) test, we observed a general
increase in the proportion of PSC recovered from the SVF
with increasing time (not significant) (Fig. 3a); however, the
absolute numbers remained consistent and the relative
rise was in fact due to a reduction in the proportion
of CD45+ haematopoietic cells (Fig. 3b).
Statistical process control over the prospective isolation
of PSCs
Since 2013, both groups at UCLA and Edinburgh have
been using the same protocol based on the improve-
ments and developments made during the process of
optimization. To assess the extent to which our process
was consistent, reproducible, and under statistical control
we used Levey-Jennings charts that show control limits 3
SDs above (upper control limit) and below (lower control
limit) the process mean. When PSC yields (per 100 ml of
lipoaspirate) obtained using the optimized protocol were
compared with the non optimized earlier protocols, it was
apparent that our optimized protocol had resulted in im-
provements in the reproducibility and purity of PSC isola-
tion (Figs 4 and 5). Levey-Jennings charts depicting
individual data points (Fig. 4) showed that mean PSC yields
Fig. 3 One-way analysis of variance analysis of the number and proportion of cells recovered with respect to storage time at 4 °C. a PSC yield (×
106) per 100 ml of lipoaspirate showing a gradual increase with longer storage times; however, this is a relative effect due to the deceasing
number of CD45+ hematopoietic cells seen in b. Green diamonds indicate the mean and 95 % confidence interval for each storage time interval,
while the gray line represents the grand or overall mean. Hrs hours, PSC perivascular stem cell, SVF stromal vascular fraction (Color figure online)
West et al. Stem Cell Research & Therapy  (2016) 7:47 Page 6 of 12
were reduced following process optimization (from 13.8 to
9.3 million PSC per 100 ml of lipoaspirate) but resulted in
quite similar PSC yields between the UCLA and Edinburgh
groups (9.2 and 9.6 million PSC)—it should be noted that
the viability of cells post optimization was higher. Further-
more, upper and lower control limits were greatly improved
following process optimization, resulting in a 53 % reduc-
tion in sample SD: 5.5 × 106 vs 10.3 × 106 PSC for the opti-
mized and nonoptimized process, respectively. The
statistical control charts thus demonstrate that our current
protocol has improved the reproducibility of PSC isolation
and confirm that both the UCLA and Edinburgh isolation
processes are under statistical control. At the same time,
contamination of sorted PSC by CD45+ haematopoietic
cells and CD31+ endothelial cells has decreased, yielding
greater than 99.5 % depletion of these cells based upon the
detection of protein tyrosine phosphatase, receptor type C
(CD45) and platelet endothelial cell adhesion molecule
PECAM1 (CD31) transcripts by real time quantitative PCR
(Fig. 5).
Discussion
Regenerative medicine is defined as the process of re-
placing, engineering, or regenerating cells, tissues, or or-
gans to restore or establish normal function. Paramount
to the clinical translation of basic research into adult stem
cell therapies is the identification of cell sources and
methods that minimize any potential risks to the patient.
These risks are mitigated when pure, well-defined popula-
tions of cells are used that have not undergone the exten-
sive ex vivo manipulation that culturing entails with its
associated risks due to infection, immunogenicity, and
genetic instability. Additionally, the future clinical adop-
tion of MSC for regenerative therapies requires a precise
delineation of cellular identity, purity, and potency as spe-
cified by the Food and Drug Administration in the April
2008 Content and Review of Chemistry, Manufacturing,
and Control Information for Human Somatic Cell Ther-
apy Investigational New Drug Applications [20], and as re-
inforced in the November 2013 Guidance for Industry:
Preclinical Assessment of Investigational Cellular and
Gene Therapy Products [21]. Clearly, progress toward the
clinical use of MSC awaits a standardized manufacturing
process that will consistently produce sufficient numbers
of MSC of defined identity, purity, and potency safely and
from easily dispensable human tissues uncompromised by
conditions that might alter their sterility, stability, im-
munogenicity, and genomic integrity.
Adipose tissue is an abundant source of perivascular as-
sociated regenerative cells that can be harvested in large
quantities even from individuals of normal BMI with min-
imal morbidity. These PSC consist of a bipartite population
of adventitial cells and pericytes which together embody
the entire regenerative potential of adipose tissue and are
well defined in their anatomical origin, immunophenotype,
and contribution to fat tissue composition [7, 10–12, 14,
19, 22, 23]. Notwithstanding their tissue origin, purified
PSC are indistinguishable from conventional MSCs in their
multidifferentiation potential [7, 10–12, 14, 19, 24–29], and
in vitro and in small animal studies have been shown to
function in hematopoietic stem cell support [30], fibrosis
[31–33], and bone [14, 19], muscle [34], pulmonary [35],
Post-optimisation
Mean = 9.3 million PSC
SD = +/- 5.5 x 10^6
Mean = 13.8 x 10^6 (SD = +/- 10.3x10^6)
Mean = 9.2 x 10^6
(SD = +/- 6.2x10^6) Mean = 9.6 x 10^6
(SD = +/- 4.9 x 10^6
Fig. 4 Statistical control chart demonstrating that optimization improved the reproducibility of PSC isolation and confirming that both the UCLA
and UK isolation processes are under statistical control. A Levey-Jennings chart depicting individual data points for PSC yield (×106) obtained from
100 ml of lipoaspirate using the UCLA isolation process, before and after optimization, as compared with the UK process (n = 131). The central
green line represents the general mean and is delimited by upper and lower control limits (red lines) based upon a 3σ interval. PSC perivascular
stem cell, SD standard deviation, SVF stromal vascular fraction, UCLA University of California at Los Angeles (Color figure online)
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peripheral nerve [36], white adipocyte [24], follicular den-
dritic cell [37], and cardiovascular [38–42] regeneration. In
some of these models, the function of PSCs was equivalent
or superior to that of conventional MSCs or other progeni-
tor populations (reviewed in [12]). Furthermore, unlike
conventional MSC, PSC do not require culture for isolation
and or purification, and have been convincingly shown to
induce greater bone formation than their unpurified coun-
terpart cell populations in the SVF [19, 43]. In this present
study, we have optimized a process to rapidly and consist-
ently purify healthy and viable PSC from moderate
amounts of lipoaspirate to high homogeneity by FACS [10,
12, 19, 44] in quantities theoretically sufficient to address
many clinical needs.
Currently, PSC isolation relies on sophisticated FACS flow
cytometers that are uncommon in clinical settings and costly
to acquire, operate, and maintain. Although clinical-grade
cell sorters are available [45], the widespread adoption of
PSC and other sorted cell therapies will require the codeve-
lopment of stem cell treatment centers like the recently
funded California Alpha-stem Cell Clinics, which are tech-
nically staffed and equipped with such instruments [46].
This analysis of 131 samples represents the largest and
most comprehensive analysis of adipose tissue stem cells
to date. We demonstrate a theoretical yield of 11.6 million
PSC per 100 ml of lipoaspirate; however, an average yield
of 9.3 million PSC per 100 ml is a more realistic and con-
sistent estimate of PSC based on process optimization and
data compiled from two different laboratories at UCLA
(9.2 million PSC from n = 109 samples) and Edinburgh
(9.6 million PSC from n = 22 samples). Given that cos-
metic liposuction procedures often exceed volumes of 1 l,
more than sufficient cells could be prospectively isolated
to satisfy a range of regenerative applications (Table 2)
based on estimates obtained from clinical trials data
(www.clinicaltrials.gov) and our own group. Nevertheless,
ex vivo culture would still be necessary for systemic condi-
tions and where multiple doses are required, such as graft
versus host disease.
The protocol presented in this work is based on the
one originally developed to purify PSC from a variety of
fetal and adult tissues [7], which was subsequently
modified specifically for adipose tissue [19]. Through
examining the health, quality, and purity of these PSC
S
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Fig. 5 Improvements in PSC purity. a Optimization of the PSC isolation process has led to increased purity of cells, as indicated by enrichment for
the adventitial cell antigen CD34 (left), and the dramatic reduction in the endothelial cell antigen CD31 (middle) and haematopoietic marker CD45
(right) by real-time quantitative PCR (n= 7; pre optimization = 4, post optimization = 3). b (Left) FSC vs SSC demonstrating the population of lymphocytes
(arrow). (Centre) Confirmation of lymphocytes by demonstration of CD45+ phenotype of the subpopulation. (Right) Selection of the CD45– depleted cellular
fraction for subsequent analysis. FSC Forward scatter, PSC perivascular stem cell, SSC side scatter
West et al. Stem Cell Research & Therapy  (2016) 7:47 Page 8 of 12
populations immediately after FACS, we noted that
large numbers of PSCs were of poor quality and in
the process of dying. We therefore sought to refine
and optimize our protocol with emphasis on consistently
delivering maximum numbers of pure and viable PSC.
There are a number of modifications that have been
made to this current protocol when compared with that
previously published by James et al. [19]. The most signifi-
cant change made was to reduce the enzymatic digestion
time down from 70 minutes to 45 minutes On close
examination of the cells following digestion, we noted that
although the length of digestion did not seem to have a
major effect on total SVF yield (45 minutes = 34.4 × 106 vs
70 minutes = 39.4 × 106 nucleated cells/100 ml of lipoaspi-
rate), the health of those cells recovered was adversely af-
fected by longer digestion times—such that significant
proportions of cells recovered immediately following
FACS were dead or apoptotic. Two further filtration steps
(100 and 40 μm) were introduced immediately following
enzymatic digestion to remove debris that were more ap-
parent with the shorter digestion time. When comparing
the number and type of cells recovered between the
current protocol and that published previously [19] it ap-
pears that there has been a large reduction in the percent-
age of pericytes retrieved (8 % vs 19.5 %), and an increase
in the adventitial cells (33 % vs 23.8 %). It is our experi-
ence that this change is more a reflection on the number
of healthy cells that can be recovered, and although the
total proportion of PSC remains similar (41 % vs 43.2 %),
the current protocol delivers healthier cells that are there-
fore more suitable for immediate use. We have noted that
the pericyte population is especially prone to damage due
to the longer digestion. Further changes were made
through the addition of an endothelial cell specific anti-
body (CD31) to eliminate these cells as part of the FACS
purification process, resulting in greater purity of the sam-
ples (Fig. 5a). This protocol relies on the selection of peri-
cytes being CD146+ and adventitial cells being CD34+ but
both of these groups were probably contaminated with
endothelial cells because subsets express both CD34 and
CD146. These cells were not present in subsequent
analysis of in-vitro populations due to the unfavorable
culture conditions for endothelial cells. We have also
noted reductions in other contaminating populations
such as the CD45+ hematopoietic cells (Fig. 5). Both
protocols utilize a CD45 antibody to deplete these
cells; however, we believe that as our experience of
this process has improved we have also been able to
set tighter FACS gates to eliminate these populations with
more accuracy (Fig. 5b). In addition to the importance of
being able to deliver a pure and defined clinical product, it
has been shown that contamination of MSC by endothe-
lial cells also inhibits their function [47, 48].
The ultimate goal is to translate our work to novel ther-
apies that address a wide range of clinical needs. The
protocol described here utilizes research-grade reagents
and therefore consideration will need to be given to trans-
lating the work for clinical use. Wherever possible we have
sought to utilize reagents that can also be bought at
clinical grade; however, there are some reagents where
alternatives may need to be sought, such as substituting
human serum albumin for BSA. Further optimization will
probably be required for this process, but the current
work will act as a benchmark for subsequent studies.
One part of the process over which we had no control
was the liposuction methods used by the surgeons
recovering the adipose tissue. Whilst we have not specif-
ically investigated the effect of different liposuction pro-
cedures on PSC yield, it is likely that variations in the
type of liposuction cannula and hence the size of fat
within the lipoaspirate will influence the digestion
process and recovery of PSC. In all of the samples we
processed, the adipose tissue was the by-product of a
cosmetic procedure and so the type of liposuction per-
formed was at the discretion of the surgeon. In future, if
liposuction is to be performed with the primary
Table 2 Potential clinical applications and the amount of adipose tissue required to provide sufficient numbers of prospectively
purified perivascular stem cells to eliminate the need for ex-vivo expansion
Clinical use Estimated number of cells required Amount of fat needed
Tissue engineered tendon 1.5 million/cm 12 ml/cm
Tissue engineered mandible 10 million/cm 80 ml/cm
Cartilage for nasal reconstruction 20 million 160 ml
Scaphoid nonunion 25 million 200 ml
Tibial nonuniona 40 million 320 ml
Total ear reconstruction 50 million 400 ml
Critical limb ischemiaa 2 million cells/kg 16 ml/kg
Graft versus host diseasea 0.5–13 million cells/kg 4.8–125 ml/kg
(repeat doses required)
aData from clinicaltrials.gov
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intention of recovering cells for clinical use we would
suggest that the liposuction procedure should also be
examined, optimized, and standardized.
There are a number of limitations of this current study
that need to be addressed. Whilst this study represents
the single largest analysis of SVF and stem/progenitor
cell content, the demographics of this cohort reflect the
unique type of patient undergoing cosmetic plastic
surgery, and might not reflect the full demographics of
people requiring stem cell therapies. Generally patients
undergoing cosmetic surgery are young to middle-age
women and free from any significant comorbidities.
Whilst the results suggest that age is not a factor in PSC
yield, the oldest patient in our study was aged 64.
Further studies are therefore required on patients at
later ages. Furthermore, our study was limited to looking
only at the number and viability of cells and did not exam-
ine their function or potency for particular regenerative
purposes; however, the developmental potential of fat-
derived PSC has been addressed in many other publica-
tions [14, 30, 49] and shown not to be significantly
affected by gender, age, and BMI [19]. Although we have
qualitative evidence to demonstrate that pericytes and ad-
ventitial cells have a similar function and potency [7, 10],
detailed assays examining this have not been performed.
This is an important issue that needs to be addressed be-
cause there is evidence from our group and others that
specific subsets of cells within the MSC/PSC family may
have specific and unique functions [30, 50].
By selecting a purified population of stem/progenitor
cells, we are more likely to increase the efficacy of these
cells by eliminating contaminating cells; however, the
effects of patient lifestyle, genetic background, and other
variables on the function of the resulting populations
should be examined because both age and disease have
been implicated in reduced function of conventional
MSC [51]. This is particularly relevant if an allogeneic
source of MSCs is to be proposed and defended as a
viable alternative to autologous cells.
Conclusions
Adipose tissue contains two anatomically and phenotyp-
ically discreet populations of MSC precursors—adventi-
tial cells and pericytes—together referred to as PSC.
More than 9 million PSCs per 100 ml of lipoaspirate can
be rapidly purified to homogeneity using flow cytometry
in clinically relevant numbers, potentially circumventing
the need for purification and expansion by culture prior
to clinical use. Modern high-speed flow cytometers can
theoretically process cells at rates well in excess of
20,000 cells/second, thus meaning tissue could be proc-
essed and purified PSC returned and administered for
therapeutic use within a single operative procedure. The
number and viability of these cells are minimally affected
by factors such as age, sex, BMI, and storage time in this
cohort; however, further studies are required to examine
the effects of age and pathology on the number and
efficacy of these cells.
Additional file
Additional file 1: presents the protocol and reagents for the purification
of PSCs from adipose tissue. (DOC 50 kb)
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